To provide readers with a review of contemporary literature describing the evolving understanding of the pseudohypoparathyroidism type 1A (PHP1A) phenotype.
INTRODUCTION
Pseudohypoparathyroidism type Ia (PHP1A) is a rare genetic disorder that is characterized by hypocalcemia and hyperphosphatemia despite elevated parathyroid hormone (PTH) levels. These biochemical changes are caused by resistance toward PTH in the proximal renal tubules, which leads to reduced or inappropriately normal synthesis of 1,25(OH)2 vitamin D as well as impaired downregulation of NPT2a and NPT2c expression, and thus reduced urinary phosphate excretion. Patients affected by PHP1A frequently develop resistance toward several other hormones, particularly thyroid-stimulating hormone (TSH), gonadotropins, and growth hormone-releasing hormone. PHP1A is furthermore characterized by phenotypic findings referred to as Albright Hereditary Osteodystrophy (AHO), which includes short stature, round facies, subcutaneous ossifications and brachydactyly. These patients can also have early onset obesity, and varying degrees of developmental delays and cognitive impairment. In contrast, most patients affected by pseudohypoparathyroidism type 1B (PHP1B) present with PTH-resistance alone, but they may also show resistance to other hormones, and some have the phenotypic changes classically associated with pseudohypoparathyroidism type 1A (PHP1A). Thus, in addition to molecular defects in the same genetic locus, there appears to be considerable phenotypical overlap between the two disorders.
The prevalence of PHP1A is not well understood. A recent article from Denmark reported a PHP1A prevalence of 1.1 per 100,000 inhabitants [1 & ]. A lower prevalence of 3.4 per million inhabitants was reported in Japan [2] . In the USA, we encountered one patient with PHP1A per 125,000 patients in a single tertiary medical center, although this likely overestimates the true prevalence due to a referral bias [3 && ]. PHP1A is caused by maternal mutations involving exons 1-13 of GNAS, the gene encoding the alpha-subunit of the stimulatory G protein (G s a) and splice variants thereof (Fig. 1) . Besides the mRNA encoding G s a, several additional sense and antisense transcripts are derived from the GNAS locus that utilize alternative first exons and promoters. These include exon A/B that gives rise to a splice variant that appears to encode an amino-terminally truncated form of G s a, whereas exon XL allows generation of an extra-large G s a variant (XLas). In addition, a noncoding antisense transcript and the 55-kDa neuroendocrine secretory protein (NESP55) are derived from the GNAS locus. Most studies have not found a genotype/phenotype relationship in PHP1A [4] , and the AHO phenotype can be seen in patients with molecular defects ranging from point mutations to epigenetic defects at GNAS [5 && ]. One recent study reported that subcutaneous ossifications were more common in patients harboring truncating versus missense mutations [6 & ]. Homozygous mutations in GNAS are lethal. Heterozygous mutations involving maternal GNAS exons 1-13 cause PHP1A. The same or similar GNAS mutations located on the paternal allele are the cause of pseudopseudohypoparathyroidism (PPHP), a disorder characterized by some AHO features, but without the hormonal resistance, without obesity, and without several other developmental defects encountered in PHP1A. This disorder is frequently only diagnosed after a woman with PPHP has a child affected by PHP1A. The fact that only maternal GNAS mutations involving G s a cause hormonal resistance lead to the hypothesis that the paternal GNAS allele is imprinted and does not contribute to the synthesis of this signaling protein in some tissues, such as proximal renal tubules, thyroid, pituitary, brown fat, and certain portions of the CNS, whereas other tissues such as the distal renal tubules and bone show normal paternal Gsa expression and thus no evidence for hormonal resistance. However, G s a protein is not always completely absent, even in tissues with predominantly maternal G s a expression. For example, paternal G s a expression in the proximal renal tubules appears to be relatively normal during infancy and early childhood, and serum calcium and phosphate levels are thus maintained within normal limits [7] . These findings suggested that the regulation of paternal G s a expression occurs in a tissue-and age-dependent manner, and that changes in G s a protein derived from the paternal GNAS allele contribute significantly to the clinical and laboratory variability observed in PHP1A patients. Because of the rarity of the disorder and an incomplete knowledge as to which tissues show preferential maternal G s a expression, some aspects of PHP1A have not been recognized until recently and are not uniformly present. The current review will be focused on these less well established abnormalities in PHP1A.
KEY POINTS
Reduced resting energy expenditure likely contributes to the early-onset obesity seen in PHP1A and adults may be at increased risk of type 2 diabetes.
Orthopedic complications, including brachydactyly, spinal stenosis, and carpal tunnel, are common in PHP1A.
Patients with PHP1A may have ear-nose-throat complications including dental anomalies, hearing loss, frequent otitis media, and decreased olfaction.
Sleep apnea is at least four times more common in children with PHP1A than similarly obese controls and polysomnography should be performed in patients with a history of snoring, daytime somnolence, or inattention. 
Metabolic complications
Obesity is typically recognized in the first 2 years of life [8] [9] [10] [11] [12] , but it is not part of the AHO spectrum as it was shown in 2007 to be a feature specific for PHP1A, but not for PPHP [8] . Interestingly, earlyonset obesity can be observed also in PHP1B, as recently documented for a patient with PHP1B because of the frequently encountered 3-kb deletion in STX16, the gene encoding syntaxin 16 [13] . Although increased food-intake through central mechanisms may contribute to weight gain in some children with PHP1A, a reduction in resting energy expenditure is likely to be the primary mechanism leading to obesity. We found a reduction in resting energy expenditure of 346.4 kcals/day (95% CI, À585.5 to À106.9) in children with PHP1A compared with obese controls [14] , which was recently confirmed by Roizen et al., who observed a similar reduction of 273.9 kcals/day (SE 60.0 kcals/day) [15 && ]. Patients with PHP1A can have increased interest in food, especially in the first 2 years of life, but older patients do not report increased hunger compared with obese controls [10] . These findings are supported by previous studies in murine models of PHP1A [16, 17] ; for example, mice with a brainspecific maternal Gnas exon 1 ablation had increased feed efficiency but normal food intake when the Gnas mutation was paternally inherited. In humans affected by PHP1A, obesity occurs despite early and adequate treatment of TSH resistance and growth hormone deficiency.
Although decreased resting energy expenditure has been seen in children with PHP1A [14, 15 && ], this finding was not replicated in adults [18] . Muniyappa et al. reported an average resting energy expenditure of 1357 AE 84 kcals/day in adults with PHP1A versus 1444 AE 71 kcals/day in matched obese controls. This reduction in energy expenditure was not significant; however, patients were matched by percentage body fat, not lean mass. It is therefore possible that the reduction in energy expenditure may become less pronounced in adulthood. Consistent with this conclusion, adults with PHP1A do have less pronounced obesity, with an average BMI of 33.8 and BMI z-score þ1.69 versus BMI z-score þ2.58 in children [8] .
A leading hypothesis is that abnormalities in hypothalamic melanocortin-4 receptor (MC4R) signaling, a G s a-coupled receptor, leads to energy imbalance and weight gain. There is evidence of reduced paternal G s a expression in the mouse hypothalamus which would explain why the obese phenotype is specific for PHP1A, not PPHP [17] . In contrast to the Gnas mouse model, however, the mc4r knockout mouse demonstrates both reduction in energy expenditure and significant hyperphagia [19] . Severe hyperphagia is also observed in patients with MC4R and POMC mutations, which is different from most patients with PHP1A [20, 21] . Recent studies have revealed that MC4R signals not only through G s a, but also G q11 a that couples to the inwardly rectifying potassium channel, Kir7.1 [22, 23] . The classic, G s a-coupled signaling pathway of MC4R regulates the increase in sympathetic nervous system tone whereas the Kir7.1 and G q11 a pathways are linked to changes in food intake. Two independent signaling pathways can thus explain the differences in the obesity phenotype seen in PHP1A and MC4R deficiency.
Despite the plateau in weight gain that becomes apparent toward the end of the second decade of life, adults with PHP1A can have reduced insulin sensitivity as measured by oral glucose and mixed meal tolerance tests compared with obese controls [18] . Many reports of adults with PHP1A also note glucose intolerance or type 2 diabetes [18, 24, 25] , whereas children with PHP1A showed less insulin resistance than obese controls [14, 26] . However, children with PHP1A still have an increased risk of impaired glucose tolerance [26] , suggesting impaired beta cell function. Changes in insulin action may also be mediated through the central G s a-coupled melanocortin pathway [27] . Because of the prevalent obesity and increased risk of diabetes, patients with PHP1A should be monitored for the development of glucose intolerance.
Orthopedic complications
Brachydactyly is a classic feature of PHP1A (Fig. 2) [28], which is also observed in other conditions, for example in patients with acrodysostosis because of heterozygous mutations in PDE4D or the PTHrelated peptide (PTHrP) [29, 30] . The typical pattern in PHP1A is shortening of the distal phalanx of the thumb and the third to fifth metacarpals. The proposed mechanism is insufficient signaling at the PTH/PTHrP receptor, which results in accelerated differentiation of proliferating chondrocytes into hypertrophic cells and thus premature closure of the epiphyses [31] [32] [33] . Brachydactyly may be more common in patients harboring missense versus truncating mutations [6 & ]. Early closure of the epiphyses of other bones most likely contributes to the short stature found in adults with PHP1A. As brachydactyly requires epiphyseal closure, it is not always present at a young age but may instead develop gradually during early childhood [34, 35] , which is different from the findings in patients with PDE4D and PRKAR1A mutations [36] . Short stature is also a characteristic feature of PPHP thus raising the possibility that G s a haploinsufficiency, rather than imprinted G s a expression in the growth plate is responsible for accelerated chondrocyte maturation.
Possibly because of the brachydactyly, the majority of children with PHP1A have difficulty with fine motor skills, such as handwriting, and thus should receive occupational therapy services in early childhood [37] . Carpal tunnel syndrome is more common in patients with PHP1A with 67% of patients reporting symptoms versus 15% of the general population [37] . Symptoms of carpal tunnel syndrome may begin at a young age, even in childhood [37] . It is not clear why only some patients with PHP1A develop carpal tunnel syndrome, but brachydactyly or other hand/wrist anthropometric features of AHO, rather than abnormalities in mineral ion homeostasis may contribute to the increased prevalence. This conclusion is supported by the finding of an equally high incidence of carpal tunnel syndrome in PPHP patients, that is patients with normal calcium and phosphate homeostasis [37] . Because symptoms of carpal tunnel syndrome overlap with symptoms of hypocalcemia (tingling and numbness), it can be difficult to diagnose carpal tunnel syndrome in patients with PHP1A. We recommend that all PHP1A and PPHP patients receive formal evaluation of their fine motor skills and that occupational therapy is offered as early as possible.
Symptomatic spinal stenosis is an increasingly recognized complication of pseudohypoparathyroidism, with more than 10 case reports in the literature [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] . The classic presentation is a patient with lower extremity weakness that progresses to spastic paraparesis. Symptoms typically begin in early adulthood but have been reported in patients as young as 12 years old. Spinal stenosis appears to affect more men than women with PHP1A [49] . The location of the stenosis is most commonly cervical and thoracic. Treatment includes surgical decompression and laminectomy. Approximately half of the patients had residual deficits or progression of disease postoperatively.
Several mechanisms have been proposed to explain spinal stenosis in PHP1A. Most patients have ossification of the ligamentum flavum or the anterior/posterior longitudinal ligaments or hypertrophic bone as the cause of stenosis. Soft tissue ossifications are common in PHP1A and in the spinal column can lead to compression and symptomatic stenosis. Other patients have congenital stenosis from abnormally short pedicles, resulting in a decreased anterior-posterior spinal canal diameter. The shortened pedicles are presumed to be caused by premature closure of the physes because of abnormal PTH signaling. The obesity associated with PHP1A may also contribute to reactive bone formation and ossifications of ligaments by increasing inflammation and by direct biomechanical effects on the spine [50] .
Ear, nose, and throat complications
There are conflicting reports of sensorineural hearing loss in PHP1A [51, 52] . In our retrospective cohort (described previously [3 && ]), only two of 18 patients (11%) have sensorineural hearing loss requiring hearing aids. The majority of our pediatric patients affected by this disease (55%), however, have a history of frequent otitis media requiring tympanostomy tubes and four of 18 patients with PHP1A had chronic perforations and conductive hearing loss requiring tympanoplasty. The round face, skeletal changes, and decreased muscle tone characteristic of the AHO phenotype could potentially be associated with eustachian tube dysfunction, as seen in patients with Down's syndrome, and an increased risk of otitis media [53] . Patients with PHP1A have been described as having abnormal palates and diminished uvular and gag reflexes [54] . Dental abnormalities include enamel hypoplasia, blunted roots, and delayed tooth eruption [55, 56] , although this finding is not associated with increased plasma PTHrP as previously hypothesized [57 & ]. Further investigation is needed to better understand the head and neck anatomy of patients with PHP1A.
Patients with PHP1A have type II hyposmia; they can correctly identify undiluted solutions but not diluted solutions, and they are unaware of any defect in olfaction [51, 54, 58, 59] . Patients with PHP1B may also have a mild reduction in olfactory recognition whereas patients with PPHP have normal olfaction [58, 59] , suggesting that PTH resistance and the resulting hypocalcemia may play a role.
We recently investigated the prevalence of sleep apnea and found a 4.4-fold greater relative risk of sleep apnea in children with PHP1A compared with other obese children [3 && ]. In a cohort of 31 children with PHP1A, 52% reported snoring and 45% had been diagnosed with sleep apnea, including central and obstructive apnea, as compared to a prevalence of 5-8% in obese children [60, 61] . Obesity alone cannot explain the high rates of sleep apnea in children with PHP1A. It is therefore conceivable that decreased G s a expression in the central nervous system may directly contribute to abnormal sleep patterns. For example, in the murine disease model changes in G s a expression is disruptive to normal sleep architecture [62] . Neuromuscular and anatomical features could also contribute to sleep apnea in PHP1A, but further research is needed.
Untreated sleep apnea is associated with poor memory and concentration, increased risk of heart disease and even impaired glucose metabolism [63] [64] [65] . Effective treatment of sleep apnea may mitigate these risks and even improve school performance [66] [67] [68] . Adenotonsillectomy is first line therapy for children with sleep apnea and adenotonsillar hypertrophy, but was not effective in children with PHP1A, resulting in continued need for CPAP or BiPAP [3 && ]. There may also be pulmonary disorders associated with PHP1A, such as an increased prevalence of asthma [3 && ,15 && ]. Asthma has also been reported in patients with PHP1A, PPHP, and PHP1B [69] [70] [71] . One study found a 2.5-fold increased risk of airway infections in PHP1A [1 & ]. Because of the high rates of sleep apnea in children with PHP1A, all patients should be questioned for symptoms such as restless sleep, snoring, inattentiveness, and daytime somnolence and if symptoms are present, formal evaluation by polysomnography is recommended.
CONCLUSION
Recent efforts to characterize the nonclassic features of PHP1A have improved our understanding of this complex disorder. Many of these findings have not been studied in patients with PPHP and PHP1B; further study in these related disease manifestations will help elucidate the role of GNAS imprinting in the nonclassic features. In particular, a better understanding of the impact of G s a mutations on head and neck anatomy is needed. Longitudinal assessments could help address differences between the pediatric and adult phenotypes and the longterm risks from nonclassical complications in PHP1A.
